Navigation Links
New Data Show Efficacy of Zebinix(TM) in the Treatment of Epilepsy
Date:9/24/2008

-2093-302 Study. Abstract and oral communication, presented at the 8th European Congress on Epileptology, Berlin, Germany, 21-25 September 2008.

(4). Lopes-Lima J, Gil-Nagel A, Maia J et al. Efficacy and safety of eslicarbazepine acetate as add-on treatment in adults with refractory partial-onset seizures: BIA-2093-303 Study. Abstract and oral communication, presented at the 8th European Congress on Epileptology, Berlin, Germany, 21-25 September 2008.

(5). Cramer J, Maia J, Almeida L, Soares-da-Silva P. Quality-of-life improvement during long-term treatment with eslicarbazepine acetate. Abstract and poster, presented at the 8th European Congress on Epileptology, Berlin, Germany, 21-25 September 2008.

(6). Hodoba D, Członkowska A, Cramer J. Depressive symptoms improvement during long-term treatment with eslicarbazepine acetate. Abstract and poster, presented at the 8th European Congress on Epileptology, Berlin, Germany, 21-25 September 2008.

(7). Guekht A, Elger C, Halasz P et al. Long-term treatment of partial epilepsy with eslicarbazepine acetate: results of a 1-year open-label extension study. Abstract and oral communication, presented at the 8th European Congress on Epileptology, Berlin, Germany, 21-25 September 2008.

(8). WHO Atlas: Epilepsy Care in the World. WHO 2005

(9). Brodie MJ. Management strategies for refractory localization-related seizures. Epilepsia 2001;42(Suppl 3):27-30

(10). Mei PA, Montenegro MA, Guerreiro MM, Guerreiro CA. Pharmacovigilance in epileptic patients using antiepileptic drugs. Arq Neuropsiquiatr 2006 Jun;64(2A): 198-201. Epub 2006 Jun 9

For more information please contact:

BIAL (head office)

Francisco Osorio

Tel.: +351-22-986-6100

Mobile: +351-96-346-9968

francisco.osorio@bial.com

Paul Gittins

Red Health

Tel.: +44-207-025-6571

Mobile: +44-7958-533-462


SOURCE BIAL
Copyright©2008 PR Newswire.
All rights reserved

1

GOOD

Page: 1 2 3 4 5 6

Related medicine technology :

1. MicroRNA First Disclosed by Rosetta Genomics may Increase Efficacy of Imatinib (Gleevec(R)(1)) in Glioblastoma
2. Continuous Treatment With Abbotts HUMIRA(R) Achieves Superior Long-Term Efficacy for Psoriasis Patients Compared to Interrupting Treatment
3. Interface Biologics Anti-Thrombic Additives Show Equivalent Efficacy to Commercial Heparinized Coatings
4. NicOx Announces Second Naproxcinod Pivotal Phase 3 Study (302) Meets Efficacy Primary Endpoints and Supports Non-Detrimental Blood Pressure Effect
5. Alpharma Announces Positive Results From Pivotal Phase III Efficacy Trial on ALO-01 (EMBEDA(TM)) (morphine sulfate extended-release with sequestered naltrexone hydrochloride) Capsules at the American Academy of Pain Management Annual Clinical Meeting
6. Biosensors DES Demonstrates Equivalent Safety and Efficacy to Industry Leading DES in First Real World, All Comers Clinical Study
7. Isolagen, Inc. Reports Positive Top-line Results from Pivotal Phase III Studies of Isolagen Therapy(TM) in Wrinkles: Studies Meet All Primary Efficacy Endpoints and are Statistically Significant
8. Medivation Presents Positive New Data on Dimebons Long-Term Efficacy and Novel Mechanism of Action at the International Conference on Alzheimers Disease
9. Jennerex Publishes Clinical Trial Data With Lead Product JX-594 Demonstrating Efficacy Against Liver Cancer and Associated Hepatitis B Virus
10. Isolagen Completes Pivotal Efficacy Portion of Phase III Studies of Isolagen Therapy(TM) for Wrinkles
11. Eisai Provides Preliminary Efficacy Update On EORTC Phase III Trial of Dacogen(R) Versus Supportive Care in Patients With Myelodysplastic Syndromes

Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/25/2009)..., WEST PALM BEACH, Fla., Nov. 25 /PRNewswire-First...red Americans, especially the 27 million living wi...be all that happy, says audiologist Cindy Beyer. ,...Amex: EAR ), one of America,s largest hearing car...linked hearing loss to stress, frustration, and so...
(Date:11/25/2009)... , NEW YORK, Nov. 25 Reportlink... is available in its catalogue: ,, United Stat... 2015 ,, http://www.reportlinker.com/p0158733...Forecasts-to-2015.html ,, United States Dental..., Summary ,, This report is an essential sou...
(Date:11/25/2009)... , SAN DIEGO, Nov. 25 /PRNewswire-FirstCall/ ...ce company focused on developing products for mini..., announced today that it will host a conference c.../ 2:30 p.m. PT. The conference call will focus on...Company,s products and will include comments from ...
Breaking Medicine Technology:For Millions With Untreated Hearing Loss, Holiday Season Can be Especially Difficult 2For Millions With Untreated Hearing Loss, Holiday Season Can be Especially Difficult 3Reportlinker Adds United States Dental Devices Market Analysis and Forecasts to 2015 2Reportlinker Adds United States Dental Devices Market Analysis and Forecasts to 2015 3Reportlinker Adds United States Dental Devices Market Analysis and Forecasts to 2015 4Reportlinker Adds United States Dental Devices Market Analysis and Forecasts to 2015 5Reportlinker Adds United States Dental Devices Market Analysis and Forecasts to 2015 6Reportlinker Adds United States Dental Devices Market Analysis and Forecasts to 2015 7Reportlinker Adds United States Dental Devices Market Analysis and Forecasts to 2015 8Reportlinker Adds United States Dental Devices Market Analysis and Forecasts to 2015 9Reportlinker Adds United States Dental Devices Market Analysis and Forecasts to 2015 10Reportlinker Adds United States Dental Devices Market Analysis and Forecasts to 2015 11Reportlinker Adds United States Dental Devices Market Analysis and Forecasts to 2015 12Reportlinker Adds United States Dental Devices Market Analysis and Forecasts to 2015 13NuVasive Announces Conference Call and Webcast Regarding Reimbursement 2NuVasive Announces Conference Call and Webcast Regarding Reimbursement 3NuVasive Announces Conference Call and Webcast Regarding Reimbursement 4 2415 million stimulus award creates national consortium for revealing scientific resources 10601 1 2415 million stimulus award creates national consortium for revealing scientific resources 10601 2 2415 million stimulus award creates national consortium for revealing scientific resources 10601 3Developmental drug may help bone fractures heal after radiation exposure 60527 1Delays in Lung Cancer Care More Common in Public Hospitals 60523 1
...studies presented at the National Lipid ...RSIPPANY, N.J., May 30 Daiichi Sankyo, Inc.,annou...ee pivotal studies,demonstrated that the addition ...es treatment regimens can lower A1C in patients wi...analyses included all patients receiving,Welchol i...
...N,PHARMACEUTICALS, INC. (Nasdaq: VION ) today ann...ead anticancer agent Cloretazine(R) (VNP40101M) in...ed in posters at the 2008,American Society of Clin...Illinois., The poster (Abstract #7051) entitled "... III study of high-dose continuous infusion cytosi...
Other Medicine Technology:Welchol(TM) Lowered A1C by a Mean 1 Percent or Greater When Added to Metformin-, Insulin-, or Sulfonylurea-Based Therapy in 47 Percent of Patients Evaluated 2Welchol(TM) Lowered A1C by a Mean 1 Percent or Greater When Added to Metformin-, Insulin-, or Sulfonylurea-Based Therapy in 47 Percent of Patients Evaluated 3Welchol(TM) Lowered A1C by a Mean 1 Percent or Greater When Added to Metformin-, Insulin-, or Sulfonylurea-Based Therapy in 47 Percent of Patients Evaluated 4Welchol(TM) Lowered A1C by a Mean 1 Percent or Greater When Added to Metformin-, Insulin-, or Sulfonylurea-Based Therapy in 47 Percent of Patients Evaluated 5Welchol(TM) Lowered A1C by a Mean 1 Percent or Greater When Added to Metformin-, Insulin-, or Sulfonylurea-Based Therapy in 47 Percent of Patients Evaluated 6Vion Pharmaceuticals to Present Clinical Data on Cloretazine(R) (VNP40101M) at the ASCO(R) Annual Meeting 2Vion Pharmaceuticals to Present Clinical Data on Cloretazine(R) (VNP40101M) at the ASCO(R) Annual Meeting 3
(Date:11/26/2009)...on an emotional rollercoaster, study finds , ...it the fear factor meets the jubilant sports fan. ...ially those who root for the winning team -- enjoy...sted match and victory was in doubt, producing fee... this Thanksgiving weekend as you,re glued to the ...
(Date:11/26/2009)...David Kim of the Live Life Again Center, a practic... of a growing number of physicians who are taking...onnect with individuals who are interested in surg.... Dr. Kim is utilizing Facebook to share before-an...with the community. , Dal...
(Date:11/26/2009)...on Communications announces a highly effective and...rs struggling to make an economic recovery. , ...Flu fears is the type of challenge that could send...ding to Dr. David Benton, business growth expert a...stem – The Rfactor Intensive . “Fea...
(Date:11/25/2009)... 25 When most people he...But a chiropractor can also give patients the help... Joint, which is where your jaw (mandible) contact... The most common symptoms associated with TMJ dysf... of the jaw. But many other symptoms can be cause...
(Date:11/25/2009)...f., Nov. 25 Onyx Pharm...that the company will host two investor events in ... 7, 2009 - 9:00 a.m. CT/10:00 a.m. ET ,, Prin...s surrounding carfilzomib in relapsed and/or refra...erican Society of Hematology (ASH) Annual Meeting ...
Breaking Medicine News(10 mins):Health News:Watching the Nail-Biting Big Game Hurts So Good 2Health News:Watching the Nail-Biting Big Game Hurts So Good 3Health News:Dallas Texas Weight Loss Surgeon Using Social Media To Reach Out to Patients 2Health News:Dallas Texas Weight Loss Surgeon Using Social Media To Reach Out to Patients 3Health News:Pharmacist Injects Cure for Ailing Businesses 2Health News:Onyx Pharmaceuticals Announces December 2009 Investor Events 2
...e the way to new methods for studying and finding ...of death in industrialized countries, according to...at mutations in a molecular channel found in heart...rolled in the cell could lead to new heart disease...
...rprises. They don't scrape and poke. They massage ... prescribe homeopathic remedies//. Of course...nded colleagues sceptical. Sometimes, there's only...ral Medicine Dentists. The important steps come be...
... higher than national guidelines recommend that, i...ening//, according to a study published in the iss...rican Academy of Neurology. The study of 1,...ines. TIA happens when blood flow to part of the b...
...the risk of becoming infected with tuberculosis (T...B disease//, according to an analysis of previousl...ine. About one-third of the world’s populatio...und information in the article. Active tuberculosi...
...nib, marketed by London company AstraZeneca PLC// ... of lung cancer in whom the first-line treatment h... 20 sites. The patients who have a recorded a... line treatment. Says Medical Science Director...
...d with a brain tumor which is at the stem of her b...to approach the doctor who after routine tests rev...ble brain tumor. The doctors have given her three ...r. According to the doctors, there is a 20 % chanc...
Other Medicine News:Health News:Fruit Flies May Pave Way to New Treatments for Age-related Heart Disease 2Health News:Fruit Flies May Pave Way to New Treatments for Age-related Heart Disease 3Health News:Homeopathy and Hypnosis Come to Dentistry 2Health News:Cholesterol in Stroke Patients Exceeds National Guidelines 2Health News:Susceptibility to TB is High Among the Smokers 2
Universal Adaptor Sleeve
...or biatrial stimulation. This is the first implant...ages. The patients benefit from a lasting improvem... against cardiac remodeling. Tupos LA uses biatria...symptomatic and medicine resistant atrial tachycar...
...ronization therapy defibrillator provides ventricu...ization therapy. Features: Independently programma...V) pacing and sensing. Designed to reduce irregula...rhythmias. Designed to maintain atrial-tracked ven...
...ronization therapy defibrillator provides ventricu...ization therapy. Features: Independently programma...V) pacing and sensing. Designed to reduce irregula...rhythmias. Designed to maintain atrial-tracked ven...
Medicine Products: